Tirzepatide is a cutting-edge dual GIP/GLP-1 receptor agonist. This medication has shown remarkable results in clinical trials for the treatment of type 2 diabetes. By targeting both the GIP and GLP-1 receptors, tirzepatide successfully improves glycemic management. The dual mechanism of action of tirzepatide offers multiple potential advantages o